American Society of Hematology

Figure 1.

PFS by response and MRD status. PFS by response and MRD status (10−5) among patients who achieved CR or better and were MRD negative (≥CR and MRD negative) or who achieved a response less than CR or were MRD positive (≤VGPR or MRD positive) for patients pooled from POLLUX, CASTOR, ALCYONE, and MAIA (A) and patients in POLLUX and CASTOR with ≤2 PL pooled with all patients from ALCYONE and MAIA (B). Shown are Kaplan-Meier estimates of PFS among patients in the ITT population based on the absence of MRD as measured using the threshold of 1 tumor cell per 105 white cells and response categories according to IMWG criteria.

PFS by response and MRD status. PFS by response and MRD status (10⁻⁵) among patients who achieved CR or better and were MRD negative (≥CR and MRD negative) or who achieved a response less than CR or were MRD positive (≤VGPR or MRD positive) for patients pooled from POLLUX, CASTOR, ALCYONE, and MAIA (A) and patients in POLLUX and CASTOR with ≤2 PL pooled with all patients from ALCYONE and MAIA (B). Shown are Kaplan-Meier estimates of PFS among patients in the ITT population based on the absence of MRD as measured using the threshold of 1 tumor cell per 10⁵ white cells and response categories according to IMWG criteria.

This Feature Is Available To Subscribers Only